Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?

Affiliations

¹ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece. Electronic address: dipatoulias@gmail.com.
² Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.
³ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece; Veterans Affairs Medical Center, George Washington University, Washington, DC, United States.

Comment

Dimitrios Patoulias et al. Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep.

. 2022 Aug-Sep;69(7):547-549.

doi: 10.1016/j.endien.2022.06.011.

¹ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece. Electronic address: dipatoulias@gmail.com.
² Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.
³ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece; Veterans Affairs Medical Center, George Washington University, Washington, DC, United States.

No abstract available

Comment on

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Fralick M, Schneeweiss S, Patorno E. Fralick M, et al. N Engl J Med. 2017 Jun 8;376(23):2300-2302. doi: 10.1056/NEJMc1701990. N Engl J Med. 2017. PMID: 28591538 No abstract available.
Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB, Røikjer JB, Dal J, Jensen MH. Laursen HVB, et al. Curr Drug Saf. 2021;16(1):73-81. doi: 10.2174/1574886315666200819114629. Curr Drug Saf. 2021. PMID: 32814538